Study identification

EU PAS number

EUPAS1000000442

Study ID

1000000442

Official title and acronym

Concept Elicitation Qualitative Study: Migraine Patient Experiences with Zavegepant

DARWIN EU® study

No

Study countries

United States

Study description

This is a non-interventional, cross-sectional qualitative study involving one-on-one interviews with participants from United States who have used zavegepant as an acute migraine treatment at least once in the past three months.
This qualitative study will involve conducting a 60-minute one-on-one, semi-structured interviews via online conferencing/telephone.
This methodology allows the collection of patient perception and real-world experiences regarding the use of zavegepant for migraine treatment and will provide an in-depth understanding of patient experience unmet treatment needs.
After providing their consent, a moderator will ask participants questions following a semi-structured interview guide to explore participants’ experiences with migraine, zavegepant treatment and experiences.
All interviews will be audio recorded for transcription and qualitative analysis. Participants will be informed in advance that all information will be anonymized.
Up to 20 participants will be recruited, including a mix of individuals with positive, neutral, and negative experiences with the medication, as well as varying frequencies of use.

Study status

Ongoing
Research institutions and networks

Institutions

Pfizer
First published:
01/02/2024
Institution

Contact details

Samantha Sweeney

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable